Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
AJ Martí‐Carvajal, V Anand… - Cochrane Database of …, 2015 - cochranelibrary.com
Cochrane Database of Systematic Reviews, 2015•cochranelibrary.com
Background Myelofibrosis is a bone marrow disorder characterized by excessive production
of reticulin and collagen fiber deposition caused by hematological and non‐hematological
disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative. Janus
kinase inhibitors are a novel strategy to treat people with myelofibrosis. Objectives To
determine the clinical benefits and harms of Janus kinase‐1 and Janus kinase‐2 inhibitors
for treating myelofibrosis secondary to hematological or non‐hematological conditions.
of reticulin and collagen fiber deposition caused by hematological and non‐hematological
disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative. Janus
kinase inhibitors are a novel strategy to treat people with myelofibrosis. Objectives To
determine the clinical benefits and harms of Janus kinase‐1 and Janus kinase‐2 inhibitors
for treating myelofibrosis secondary to hematological or non‐hematological conditions.
Background
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non‐hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative. Janus kinase inhibitors are a novel strategy to treat people with myelofibrosis.
Objectives
To determine the clinical benefits and harms of Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis secondary to hematological or non‐hematological conditions.
cochranelibrary.com
